Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Ono Pharmaceutical Yönetim

Yönetim kriter kontrolleri 3/4

Ono Pharmaceutical's CEO'su Gyo Sagara, Sep2008 tarihinde atandı, in görev süresi 16.08 yıldır. in toplam yıllık tazminatı ¥ 190.00M olup, şirket hissesi ve opsiyonları dahil olmak üzere 41.1% maaş ve 58.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.026% ine doğrudan sahiptir ve bu hisseler ¥ 231.83M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 4.3 yıldır.

Anahtar bilgiler

Gyo Sagara

İcra Kurulu Başkanı

JP¥190.0m

Toplam tazminat

CEO maaş yüzdesi	41.1%
CEO görev süresi	16.1yrs
CEO sahipliği	0.03%
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	4.3yrs

Son yönetim güncellemeleri

Recent updates

We Think Ono Pharmaceutical (TSE:4528) Can Stay On Top Of Its Debt

Aug 25

Ono Pharmaceutical Co., Ltd. (TSE:4528) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 04

There's No Escaping Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Muted Earnings

Jun 24

Ono Pharmaceutical (TSE:4528) Has Announced A Dividend Of ¥40.00

Mar 04

Is There An Opportunity With Ono Pharmaceutical Co., Ltd.'s (TSE:4528) 42% Undervaluation?

Feb 27

CEO Tazminat Analizi

Gyo Sagara'un ücretlendirmesi Ono Pharmaceutical'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	JP¥121b
Mar 31 2024	JP¥190m	JP¥78m	JP¥128b
Dec 31 2023	n/a	n/a	JP¥128b
Sep 30 2023	n/a	n/a	JP¥125b
Jun 30 2023	n/a	n/a	JP¥115b
Mar 31 2023	JP¥228m	JP¥77m	JP¥113b

Tazminat ve Piyasa: Gyo 'ın toplam tazminatı ($USD 1.32M ) JP pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 1.11M ).

Tazminat ve Kazançlar: Gyo 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Gyo Sagara (66 yo)

16.1yrs

Görev süresi

JP¥190,000,000

Tazminat

Mr. Gyo Sagara has been the Chief Executive Officer at Ono Pharmaceutical Co., Ltd since April 01, 2024 and serves as it’s Director and served as its President since September 2008 until April 01, 2024 and...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gyo Sagara	CEO & Chairman of the Board	16.1yrs	JP¥190.00m	0.026% ¥ 234.0m
Toichi Takino	President	less than a year	Veri yok	0.0092% ¥ 83.9m
Masaki Ito	Corp. Offcr. and Div. Dir. of Corp. Strategy & Planning	1.3yrs	Veri yok	Veri yok
Takehiro Yamada	Corporate Officer & Head of Risk and Compliance Management Department	1.8yrs	Veri yok	Veri yok
Satoshi Takahagi	Managing Executive Officer	no data	Veri yok	Veri yok
Masayuki Tanigawa	Corporate Officer & Head of Business Strategy Headquarters	1.8yrs	Veri yok	Veri yok
Toshihiro Tsujinaka	Ex. EO, Executive Dir. of Sus. Promotion Corp. Strategy & Planning and Representative Director	1.8yrs	Veri yok	0.0060% ¥ 54.6m
Hiromu Habashita	Corporate Officer & Deputy Executive Director	no data	Veri yok	Veri yok
Shinji Takai	Corporate Officer & Head of Medical Affairs	no data	Veri yok	Veri yok
Akira Takada	Managing Executive Officer & CMC / Production Division Chief	no data	Veri yok	Veri yok
Tatsuya Okamoto	Head of Development Div.	no data	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim: 4528 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gyo Sagara	CEO & Chairman of the Board	18.3yrs	JP¥190.00m	0.026% ¥ 234.0m
Toichi Takino	President	4.3yrs	Veri yok	0.0092% ¥ 83.9m
Toshihiro Tsujinaka	Ex. EO, Executive Dir. of Sus. Promotion Corp. Strategy & Planning and Representative Director	4.3yrs	Veri yok	0.0060% ¥ 54.6m
Shusaku Nagae	Independent Outside Director	3.3yrs	Veri yok	Veri yok
Akiko Tanabe	Outside Audit & Supervisory Board Member	4.3yrs	Veri yok	Veri yok
Yasuo Hishiyama	Outside Audit & Supervisory Board Member	8.3yrs	Veri yok	Veri yok
Kiyoaki Idemitsu	Audit & Supervisory Board Member	less than a year	Veri yok	0.0032% ¥ 29.2m
Masao Nomura	Independent Outside Director	6.3yrs	Veri yok	Veri yok
Akiko Okuno	Independent Outside Director	4.3yrs	Veri yok	Veri yok
Hironobu Tanisaka	Chairman of Audit Supervisory Board	3.3yrs	Veri yok	0.00043% ¥ 3.9m

4.3yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4528 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).

Ono Pharmaceutical Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 20, 2024

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

Less than half of directors are independent

Recent updates

Upcoming dividend of JP¥40.00 per share

We Think Ono Pharmaceutical (TSE:4528) Can Stay On Top Of Its Debt

Ono Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Oct 31, 2024

Ono Pharmaceutical Co., Ltd. Announces U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Ono Pharmaceutical Co., Ltd. (TSE:4528) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

European Medicines Agency Accepts Deciphera's Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Final dividend of JP¥40.00 announced

Consensus EPS estimates fall by 23%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

There's No Escaping Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Muted Earnings

Price target decreased by 10% to JP¥2,336

Ono Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Ono Pharmaceutical Co., Ltd. (TSE:4528) completed the acquisition of Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) from BlackRock, Inc. (NYSE:BLK), Deerfield Capital, L.P., Redmile Group, LLC Brightstar Associates, LLC and others.

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 10%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 20, 2024

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024

ONO Pharmaceuticals, Co., Ltd. Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL

Upcoming dividend of JP¥40.00 per share

Ono Pharmaceutical (TSE:4528) Has Announced A Dividend Of ¥40.00

Is There An Opportunity With Ono Pharmaceutical Co., Ltd.'s (TSE:4528) 42% Undervaluation?

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Ono Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

Price target increased by 7.4% to JP¥2,935

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of JP¥40.00 per share at 2.8% yield

Ono Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 01, 2023

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ono Pharmaceutical Co., Ltd. (TSE:4528) announces an Equity Buyback for 19,000,000 shares, representing 3.89% for ¥50,000 million.

Now 20% undervalued after recent price drop

Ono Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Now 21% undervalued after recent price drop

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023

Full year 2023 earnings: EPS misses analyst expectations

Upcoming dividend of JP¥33.00 per share at 2.4% yield

Price target decreased by 7.4% to JP¥3,292

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ono Pharmaceutical Co., Ltd. (TSE:4528) acquired Research assets related to multiple research-stage oncology programs from KSQ Therapeutics, Inc.

Ono Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

Less than half of directors are independent

Second quarter 2023 earnings: EPS exceeds analyst expectations

Upcoming dividend of JP¥33.00 per share

Ono Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 21% undervalued

Ono Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022

Full year 2022 earnings: EPS misses analyst expectations

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

Consensus EPS estimates fall by 11%

Now 21% undervalued

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 11, 2022

Upcoming dividend of JP¥28.00 per share

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ono Pharmaceutical Co., Ltd. (TSE:4528) announces an Equity Buyback for 11,000,000 shares, representing 2.2% for ¥30,000 million.

Second quarter 2022 earnings released: EPS JP¥44.51 (vs JP¥36.77 in 2Q 2021)

Upcoming dividend of JP¥28.00 per share

Exelixis, Inc. Announces Partner Takeda Pharmaceutical Company Limited and Ono Receive Approval in Japan for CABOMETYX in Combination with Opdivo for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

First quarter 2022 earnings released: EPS JP¥48.23 (vs JP¥43.07 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥151 (vs JP¥118 in FY 2020)

Full year 2021 earnings released: EPS JP¥151 (vs JP¥118 in FY 2020)

Upcoming dividend of JP¥22.50 per share

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 11, 2021

New 90-day low: JP¥3,020

Third quarter 2021 earnings released: EPS JP¥53.37 (vs JP¥38.09 in 3Q 2020)